The FDA's Antimicrobial Drugs Advisory Committee (AMDAC) voted 14-4 Thursday in support of the use of TB Alliance's pretomanid as part of a combination regimen to treat the most resistant cases of tuberculosis (TB). Regimen was the key word. "I'm voting for a regimen, not a single drug," said Matthew Goetz, a professor at the David Geffen School of Medicine at the University of California-Los Angeles and chief of the infectious diseases division at the Veterans Affairs Greater Los Angeles Healthcare System.